日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity

对ICU和非ICU COVID-19患者体内冠状病毒抗体反应的全面分析表明,针对SARS-CoV-2刺突蛋白的IgG3是疾病严重程度的关键生物标志物。

Fatma H Ali ,Giusy Gentilcore ,Hadeel T Al-Jighefee ,Sara Ahmad Taleb ,Ali Ait Hssain ,Hamda A Qotba ,Asmaa A Al Thani ,Laith J Abu Raddad ,Gheyath K Nasrallah ,Jean-Charles Grivel ,Hadi M Yassine

Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination

MERS-CoV 感染和 SARS-CoV-2 疫苗接种患者的广泛反应性评估

Hadeel T Zedan, Maria K Smatti, Swapna Thomas, Gheyath K Nasrallah, Nahla M Afifi, Ali Ait Hssain, Laith J Abu Raddad, Peter V Coyle, Jean-Charles Grivel, Muna A Almaslamani, Asmaa A Althani, Hadi M Yassine

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

SARS-CoV-2 疫苗突破性感染、再感染和原发性感染的相对传染性

Laith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, Patrick Tang, Peter Coyle, Mohammad R Hasan, Hadi M Yassine, Fatiha M Benslimane, Hebah A Al-Khatib, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F Abdul-Rahim,

Comparative analysis of within-host diversity among vaccinated COVID-19 patients infected with different SARS-CoV-2 variants

感染不同 SARS-CoV-2 变体的 COVID-19 疫苗接种患者的宿主内多样性比较分析

Hebah A Al-Khatib, Maria K Smatti, Fatma H Ali, Hadeel T Zedan, Swapna Thomas, Muna N Ahmed, Reham A El-Kahlout, Mashael A Al Bader, Dina Elgakhlab, Peter V Coyle, Laith J Abu-Raddad, Asma A Al Thani, Hadi M Yassine

COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar

COVID-19 风险评分作为指导有针对性检测的公共卫生工具:卡塔尔的一项示范研究

Laith J Abu-Raddad, Soha Dargham, Hiam Chemaitelly, Peter Coyle, Zaina Al Kanaani, Einas Al Kuwari, Adeel A Butt, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F Abdul Rahim, Gheyath K Nasrallah, Hadi M Yassine, Mohamed G Al Kuwari, Hamad Eid Al Romaih

Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study

卡塔尔 SARS-CoV-2 B.1.1.7 变体的引入和扩展以及再感染:一项全国代表性队列研究

Laith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, Peter Coyle, Joel A Malek, Ayeda A Ahmed, Yasmin A Mohamoud, Shameem Younuskunju, Patrick Tang, Zaina Al Kanaani, Einas Al Kuwari, Adeel A Butt, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F Abd

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

SARS-CoV-2 抗体阳性可预防至少七个月的再感染,有效率为 95%

Laith J Abu-Raddad, Hiam Chemaitelly, Peter Coyle, Joel A Malek, Ayeda A Ahmed, Yasmin A Mohamoud, Shameem Younuskunju, Houssein H Ayoub, Zaina Al Kanaani, Einas Al Kuwari, Adeel A Butt, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F Abdul Rahim, Ghey

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

卡塔尔晚期 SARS-CoV-2 疫情特征

Laith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, Zaina Al Kanaani, Abdullatif Al Khal, Einas Al Kuwari, Adeel A Butt, Peter Coyle, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Robert C Owen, Hanan F Abdul Rahim, Samya A Al Abdulla, Mohamed G Al Kuwari, Mujeeb C Kandy, Hatoun S